Is the outlook changing for patients with renal cell cancer?
- 31 December 1990
- journal article
- review article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 26 (8) , 860-862
- https://doi.org/10.1016/0277-5379(90)90183-t
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- An Assessment of the Current Use of Human Interferons in Therapy of Urological CancersJournal of Urology, 1989
- Deoxyribonucleic Acid Content and Medroxyprogesterone Acetate Treatment in Metastatic Renal Cell CarcinomaJournal of Urology, 1989
- Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignanciesCancer Treatment Reviews, 1989
- Immunologic study of human recombinant interleukin-2 (low dose) in patients with advanced renal cell carcinomaUrology, 1989
- Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancerCancer, 1988
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephromaCancer Chemotherapy and Pharmacology, 1985
- Solitary Metastasis from Renal Cell CarcinomaJournal of Urology, 1975
- Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal CancerBritish Journal of Cancer, 1971